IceCure’s ProSense Cryoablation System Studied as a Potential Substitute for Lumpectomy for Tumors < 15 mm

November 1, 2021—IceCure Medical Ltd., an Israel-based developer of next-generation minimally invasive cryoablation technology that destroys tumors by freezing, announced the publication of findings on the company’s ProSense percutaneous ultrasound-guided cryoablation system.

The study, which is titled “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,” was published by Hisanori Kawamoto, MD, et al online in the Journal of Cancer Therapy. Dr. Kawamoto is from the Department of Breast Surgery Breast & Imaging Center at St. Marianna University School of Medicine in Kawasaki, Japan.

The independent study conducted at the St. Marianna University Breast & Imaging Center enrolled eight female patients, mean age 62 years (53-72 years), diagnosed with invasive ductal carcinoma tumors.

Percutaneous ultrasound-guided cryoablation of the breast tumor was performed using IceCure’s ProSense under local anesthesia without the need for subsequent resection. The procedure lasted for 40 minutes on average. All patients received radiation therapy and endocrine therapy. The patients were followed using vacuum-assisted biopsy, mammography, MRI, and Moiré topography for cosmetic outcomes.

The article concludes that although conducted on a limited number of patients, the data show the feasibility of cryoablation for the elimination of small malignant lesions in the breast, along with promising safety prospects.

In addition, according to the article, percutaneous cryoablation of early-stage low-risk breast cancer tumors ≤ 15 mm presents a potential substitute for lumpectomy, offering encouraging short- to midterm oncology results with good cosmesis outcomes. Patients would be able to benefit from local anesthesia in an outpatient setting and shorter recovery period advised IceCure.